nav emailalert searchbtn searchbox tablepage yinyongbenwen piczone journalimg journalInfo searchdiv qikanlogo popupnotification paper paperNew
2025, 08, v.66 817-825
补肾乳岩方治疗冲任失调型绝经前乳腺癌内分泌强化治疗患者44例随机对照临床观察
基金项目(Foundation): 国家中医药管理局国家中医优势专科建设单位项目(国中医药医政函[2024]90号); 河南省中医药科学研究专项(2022ZY1048); 郑州市科学技术局郑州市医疗卫生领域科技创新指导计划项目(2024YLZDJH069)
邮箱(Email): cxf9939@163.com;
DOI: 10.13288/j.11-2166/r.2025.08.011
摘要:

目的 观察补肾乳岩方对冲任失调型绝经前乳腺癌内分泌强化治疗患者的临床疗效及安全性。方法纳入88例接受内分泌强化治疗且中医辨证为冲任失调型的绝经前乳腺癌患者,随机分为对照组和治疗组各44例。对照组予卵巢功能抑制(OFS)+内分泌治疗,治疗组在对照组的基础上给予口服补肾乳岩方治疗。两组均连续治疗3个月,观察并比较两组患者治疗前后乳腺癌患者生命质量测定量表(FACT-B)、改良版Kupperman评分、T细胞亚群(CD3+、CD4+、CD8+、CD4+/CD8+值)水平、性激素六项[雌激素(E2)、黄体生成素(LH)、卵泡刺激素(FSH)、孕酮(P)、睾酮(T)、催乳素(PRL)]水平、肿瘤标志物[癌胚抗原(CEA)、糖类抗原125 (CA125)、糖类抗原153 (CA153)]水平及中医证候积分、中医证候疗效;监测血常规、肝肾功能评价其安全性。结果 与本组治疗前比较,治疗后治疗组FACT-B各模块评分和总分均提高、对照组治疗后的社会/家庭状况评分降低,且治疗后治疗组的各领域评分和总分均较对照组提高(P<0.05或P<0.01)。治疗后治疗组改良版Kupperman评分、中医证候积分均较治疗前降低,且均低于对照组(P<0.01)。治疗后治疗组的CD3+、CD4+水平较治疗前升高,且高于对照组(P<0.05)。治疗后治疗组血清T低于对照组(P<0.05)。治疗组中医证候疗效总有效率为67.44%,高于对照组的23.26%(P<0.05)。两组患者治疗前后血常规、肝肾功能指标均未见明显异常。结论 补肾乳岩方可提高绝经前乳腺癌内分泌强化治疗患者的生活质量、减轻症状,提高患者血清CD3+、CD4+水平及临床疗效,且安全性较好。

Abstract:

Objective To observe the clinical efficacy and safety of Bushen Ruyan Formulation (补肾乳岩方, BRF) in treating premenopausal breast cancer patients of disharmony of the chong (冲) and ren (任) meridian type under endocrine intensive therapy. Methods A total of 88 premenopausal breast cancer patients who received endocrine intensive therapy and were diagnosed with disharmony of the chong and ren meridian by traditional Chinese medicine(TCM) were included and randomly divided into a control group and a treatment group, with 44 cases in each group. The control group received ovarian function suppression(OFS) combined with endocrine therapy, while the treatment group was given oral BRF additionally. Both groups were treated for three months. The clinical efficacy was evaluated by comparing the pre-and post-treatment results of the Functional Assessment of Cancer Therapy-Breast(FACT-B), modified Kupperman score, T cell subsets(CD3+, CD4+, CD8+, CD4+/CD8+), sex hormone levels, including estradiol(E2), luteinizing hormone(LH), follicle-stimulating hormone(FSH), progesterone(P), testosterone(T), and prolactin(PRL), tumor markers, such as carcinoembryonic antigen(CEA), carbohydrate antigen 125(CA125), and carbohydrate antigen 153(CA153), TCM syndrome score, and TCM syndrome efficacy. Blood routine tests, liver function and kidney function were monitored to assess safety. Results The FACT-B scores of each domains and the total scores of the treatment group increased, while the social/family status score of the control group decreased. The treatment group had significantly higher scores in all domains and total score compared to the control group(P<0. 05 or P<0. 01). The modified Kupperman score and TCM syndrome score of the treatment group decreased, and were lower than those of the control group(P<0. 01). The levels of CD3+ and CD4+ in the treatment group increased, and were higher than those of the control group(P<0. 05). Serum testosterone levels in the treatment group were lower than those in the control group(P<0. 05). The total effective rate of TCM syndrome efficacy in the treatment group was 67. 44%, significantly higher than the 23. 26% in the control group(P<0. 05). No significant abnormalities were observed in the blood routine tests or liver/kidney function indicators in either group before or after treatment. Conclusion BRF can effectively improve quality of life, alleviate symptoms, increase serum CD3+ and CD4+ levels, and enhance clinical efficacy in premenopausal breast cancer patients undergoing endocrine intensive endocrine therapy. It is also safe with no significant adverse effects.

参考文献

[1]SUNG H, FERLAY J, SIEGEL RL, et al. Global Cancer Statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin, 2021,71(3):209-249.

[2]王莉杰,刘佳惠,李旭英,等.中国乳腺癌患者辅助内分泌治疗依从性的系统评价[J].中国循证医学杂志,2023,23(2):153-158.

[3]胡伟娇,施雁,刘贤亮,等.乳腺癌患者内分泌治疗的服药依从性与健康心理控制源及社会支持的相关性[J].国际老年医学杂志,2023,44(1):9-13.

[4]吴晶晶,张妍,林琳,等. ER和PR阴性乳腺癌雄激素受体与HER2表达相关性及其临床意义[J].中华肿瘤防治杂志,2016,23(23):1544-1549.

[5]中国抗癌协会乳腺癌专业委员会.中国早期乳腺癌卵巢功能抑制临床应用专家共识(2024年版)[J].中国癌症杂志,2024,34(3):316-334.

[6]河南省肿瘤诊疗质量控制中心乳腺癌专家委员会.河南省肿瘤诊疗质量控制中心早期乳腺癌内分泌治疗专家共识[J].中华肿瘤防治杂志,2023,30(24):1481-1485.

[7]中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2021年版)[J].中国癌症杂志,2021,31(10):954-1040.

[8]PAGANI O, REGAN MM, WALLEY BA, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer[J]. N Engl J Med,2014,371(2):107-118.

[9]吕灵艳.耳穴揿针治疗乳腺癌相关围绝经期综合征的临床研究[D].北京:北京中医药大学,2020.

[10]刘晓蒙,王国鑫,薛明新.乳腺癌芳香化酶抑制剂相关关节疼痛中西医诊疗进展[J].辽宁中医药大学学报,2021,23(5):59-64.

[11]赵艳玲,张志芳.国家标准中医临床诊疗术语:证治要览[M].长沙:湖南科学技术出版社,1999:44-45.

[12]郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:29-30.

[13]FRIENDLANDER AH,ETTINGER RL. Karnofsky performance status scale[J]. Spec Care Dentist,2009,29(4):147-148.

[14]刘建平.临床试验样本含量的计算[J].中国中西医结合杂志,2003,23(7):536-538.

[15]BRADY MJ, CELLA DF, MO F, et al. Reliability and validity of the Functional Assessment of Cancer TherapyBreast quality-of-life instrument[J]. J Clin Oncol, 1997,15(3):974-986.

[16]万崇华,张冬梅,汤学良,等.乳腺癌患者生命质量测定量表(FACT-B)中文版的修订[J].中国心理卫生杂志,2003,17(5):298-300.

[17]李红霞,蔡凯,杨杨.潜阳封髓丹加减治疗绝经前Luminal A型乳腺癌患者他莫昔芬治疗后类更年期综合征的疗效及对睡眠质量和生活质量的影响[J].现代中西医结合杂志,2020,29(3):250-254.

[18]顾文静,平小英,胡平.逍遥散对乳腺癌内分泌治疗后类更年期综合征患者PFS评分、性激素水平及睡眠质量的影响[J].四川中医,2022,40(10):163-165.

[19]KUPPERMAN HS, BLATT MH, WIESBADER H, et al.Comparative clinical evaluation of estrogenic preparations by the menopausal and amenorrheal indices[J]. J Clin Endocrinol Metab,1953,13(6):688-703.

[20]吴杨乔,刘雁峰.围绝经期综合征相关评分量表临床研究及应用概况[J].中华中医药杂志,2019,34(10):4765-4769.

[21]赵伟鹏,李鹤,姜欣,等.从“湿热内蕴,郁遏卫阳”谈化疗后白细胞减少症的中医辨治[J].中国中医基础医学杂志,2021,27(6):1019-1021.

[22]裴俊文,孙太振.丹栀逍遥散合二仙汤治疗乳腺癌内分泌治疗后类更年期综合征[J].中医学报,2019,34(9):1973-1976.

[23]王家豪,陈仁寿.附子汤组方思路与证治要点[J].河南中医,2023,43(10):1474-1477.

[24]安健,孙蓬明. T淋巴细胞亚群检测在子宫内膜癌中的应用价值[J].中国妇产科临床杂志,2020,21(4):428-431.

[25]臧智超,梁俊青.乳腺癌患者新辅助化疗前后CD3+CD4+及NK细胞相关性分析[J].世界最新医学信息文摘,2019,19(50):41-42.

[26]王成,王晓玲,李江涛,等.自拟舒肝益肾方联合内分泌治疗激素依赖型乳腺癌疗效[J].辽宁中医杂志,2023,50(8):115-119.

[27]唐潇然,呼健,赵鹏飞.香砂六君子汤加减对胃癌患者术后肠黏膜屏障及免疫状态的影响[J].中国医药,2023,18(12):1874-1878.

[28]钟融,吴雪卿,瞿文超,等.乳癌术后方对乳腺癌术后患者生活质量、肿瘤标志物和外周血T细胞亚群的影响[J].现代生物医学进展,2022,22(6):1064-1068.

[30]董长鸿,封岩,江艳婷,等.外周血T淋巴细胞亚群与接受卡瑞利珠单抗治疗的晚期非小细胞肺癌患者预后的关系[J].肿瘤防治研究,2024,51(3):185-190.

[31]《围绝经期综合征(更年期综合征)重点人群治未病干预指南》编写组.围绝经期综合征(更年期综合征)重点人群治未病干预指南[J].北京中医药大学学报,2023,46(8):1048-1062.

[32]孙晓寅,莊志刚.性激素与乳腺癌关系的研究进展[J].中国新药与临床杂志,2018,37(9):571-576.

[33]周林菊.激素替代疗法治疗更年期综合征患者的疗效分析[J].中国全科医学,2021,24(S2):88-90.

[34]王鹏,江晓华,冉凤伟,等.多种血清肿瘤标志物在转移性乳腺癌中的诊断价值及临床意义[J].国际检验医学杂志,2020,41(21):2595-2598.

[35]尹立娜,龚恒文,赵东霞,等.血清标志物在乳腺癌骨转移诊断中的临床价值[J].中华肿瘤防治杂志,2024,31(2):95-100.

[36]周颖,钟凌云,罗红兵,等.基于UPLC-MS/MS探讨“建昌帮”阴附片、阳附片、淡附片炮制过程化学成分差异研究[J].中国中药杂志,2023,48(23):6387-6395.

基本信息:

DOI:10.13288/j.11-2166/r.2025.08.011

中图分类号:R273

引用信息:

[1]王泽鹏,程旭锋,袁江山等.补肾乳岩方治疗冲任失调型绝经前乳腺癌内分泌强化治疗患者44例随机对照临床观察[J].中医杂志,2025,66(08):817-825.DOI:10.13288/j.11-2166/r.2025.08.011.

基金信息:

国家中医药管理局国家中医优势专科建设单位项目(国中医药医政函[2024]90号); 河南省中医药科学研究专项(2022ZY1048); 郑州市科学技术局郑州市医疗卫生领域科技创新指导计划项目(2024YLZDJH069)

检 索 高级检索

引用

GB/T 7714-2015 格式引文
MLA格式引文
APA格式引文